12th Congress of the Polish Transplantation SocietyOrgan procurementA Cell Graft or a Drug? Legal and Practical Aspects of Somatic Cells Application in Graft-Versus-Host Disease Experimental Treatment: The Polish Experience
Section snippets
Mesenchymal Stem/Stromal Cells
MSCs are defined as self-renewing, multipotent progenitor cells with multilineage potential. In 2006, the minimal criteria for definition of MSCs were published by the Mesenchymal and Tissue Stem Cell Committee of the International Society for Cellular Therapy [5]. MSCs have been shown to possess an enormous number of immunomodulatory properties in vitro and in vivo, regulating both adaptive and innate immune responses [3]. Therefore, in the last decade a large number of clinical studies were
Summary
Attempts to treat seriously ill patients, including patients with steroid-refractory GvHD, by MSC or Treg application have been undertaken in Poland [24], [25]. The exact number of cases is not known—there is no legal obligation to provide official statistics. However, taking into account the lack of registered clinical trials in Poland e.g. in the field of GvHD treatment, it can be assumed that administrated cells were in the majority of cases HE-ATMPs by law. It means that everything that was
References (25)
- et al.
Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement
Cytotherapy
(2006) - et al.
Association of Foxp3 regulatory gene expression with graft-versus-host disease
Blood
(2004) - et al.
First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4+CD25+CD127− T regulatory cells
Clin Immunol
(2009) - et al.
Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics
Blood
(2011) - et al.
Umbilical cord blood-derived T regulatory cells to prevent GVHD: kinetics, toxicity profile and clinical effect
Blood
(2016) - et al.
Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation
Blood
(2011) - et al.
Adoptive transfer of allogeneic regulatory T cells into patients with chronic graft-versus-host disease
Cytotherapy
(2015) - et al.
Mesenchymal stromal cells for prevention and treatment of graft-versus-host disease: successes and hurdles
Curr Opin Organ Transplant
(2015) - et al.
Concise review: acute graft-versus-host disease: immunobiology, prevention, and treatment
Stem Cells Transl Med
(2013) - et al.
Mesenchymal stem cells for the treatment and prevention of graft-versus-host disease: experiments and practice
Ann Hematol
(2013)